April 26th, 2018

A full text version of this article is available.
To access article obtain online access here or login
Worldwide Survey of the Results of Treating Gestational Trophoblastic Disease
Authors:  Ernest I. Kohorn, M.A., M.Chir. (Cantab), F.R.C.S., F.R.C.O.G., F.A.C.O.G.
  OBJECTIVE: To determine factors influencing outcome for patients with gestational trophoblastic disease (GTD) from throughout the world.

STUDY DESIGN: Physicians known to treat GTD were sent a questionnaire.

RESULTS: There were 32 responses from 17 countries, totaling 26,153 patients. Of 14,093 patients with complete mole 20.6% developed trophoblastic neoplasia, and 5.7% died. There were 10,230 patients with partial mole, of whom 6.5% received thera-py for neoplasia. There were
548 patients with post–term pregnancy choriocarcinoma, of whom 13.4% died. Of 137 patients with placental site trophoblastic tumor 16.1% died. The remaining 1,165 patients did not fit into a designated diagnostic category. The mortality rate for 2,818 patients with GTD primarily treated at a trophoblast center was 2.1%, as compared with 8% among 1,854
patients referred after failure of primary treatment (p<0.01).

CONCLUSION: Patients treated by physicians experienced in the management of trophoblastic disease have better results and survival.
Keywords:  choriocarcinoma, complete mole, gestational trophoblastic disease, molar pregnancy, partial mole, placental site trophoblastic tumor
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from